City of Hope Enters Licensing Agreements with CytoImmune Therapeutics Inc. to Develop Portfolio of Chimeric Antigen Receptor-Natural Killer Therapies – About Your Online Magazine


The licensing and development agreements will promote several immunotherapies

City of hope, a world-renowned independent research and treatment center for cancer, diabetes and other potentially fatal diseases, and CytoImmune Therapeutics Inc. (“CytoImmune”), a clinical biopharmaceutical company focused on the marketing of new cancer immunotherapy products, announced that it has entered into exclusive license agreements worldwide.

This press release features multimedia. See the full release here: https://www.businesswire.com/news/home/20210408005072/en/

City of Hope and CytoImmune Therapeutics Inc. have entered into exclusive license agreements worldwide for various patent applications related to methods to generate a large number of fully functional natural killer (NK) cells derived from umbilical cord blood and chimeric receptor compositions (CAR) for targeting NK cells to tumors. (Photo: CytoImmune Therapeutics Inc.)

The agreements include licenses for several patent applications related to methods for generating a large number of fully functional natural killer (NK) cells derived from umbilical cord blood and chimeric receptor (CAR) compositions to target NK cells to tumors. They include a prostate stem cell antigen (PSCA) CAR to treat pancreatic, gastric, bladder, prostate and some lung cancer, a programmed death ligand 1 (PD-L1) + NK cell for use in treatment of lung cancer and similar to fms tyrosine kinase 3 (FLT3) CAR NK cell therapy for use in the treatment of acute myeloid leukemia.

Licensed technologies are based on discoveries by CytoImmune co-founders Jianhua Yu, Ph.D., professor, Department of Hematology and Hematopoietic Cell Transplantation in the City of Hope, and Michael A. Caligiuri, M.D., president of the City of Hope National Medical Center, who together have more than 55 years of experience in NK cell biology and more than 500 original peer-reviewed publications on NK cells and cancer.

“As an independent institution dedicated to advancing the fight against cancer, City of Hope is committed to finding breakthrough discoveries and treatments, and NK cell therapies offer great hope for patients,” said Robert Stone, president and CEO of City of Hope and the Helen and Morgan Chu Distinguished President of the Executive Director. “We are proud of the discoveries of Dr. Caliguiri and Dr. Yu and we are pleased to sign these agreements with CytoImmune.”

CAR NK therapies are designed to harness the power of healthy donor NK cells, which in turn are “designed” to aggressively treat cancer patients, minimizing the side effects of treatment. City of Hope, a recognized leader in CAR T cell therapies for solid and blood cancers, has treated more than 600 patients since its CAR T research began in the late 1990s. The institution continues to have one of the most comprehensive health care facilities in the country. CAR T cell GMP and CAR T cell clinical research programs worldwide, with about 50 CAR T cell assays currently taking place in City of Hope or about to open.

“CytoImmune has expanded our productive partnership with City of Hope, a leader in immunotherapy research, and we have solidified our position as leaders in NK cell technology,” said Rich Santulli, President and CEO of CytoImmune. “Drs. Caligiuri and Yu have worked together for nearly 20 years and have made important and fundamental discoveries in NK cell science. With these agreements, we gain access to technologies that will generate an abundant supply of our proprietary designed and enhanced NK cells that can kill selectively both blood and solid tumor cells. We hope that by promoting this research, we will benefit patients who need new treatment options. “

“As the scientific founder of CytoImmune, I am pleased to see the company expand its collaboration with City of Hope. NK cell therapy holds great promise for the treatment of blood and solid tumor cancers. We are excited to see this therapy promising. moving forward with the goal of helping even more cancer patients, “said Caligiuri, illustrious president of chief physician Deana and Steve Campbell.

Yu and Caligiuri also have many patents among them for many first in the development of human NK cells, survival, activation, in vivo modulation and preclinical models of human NK CAR therapy for cancer. More than 1,000 cancer patients have been treated in protocols designed or co-designed by Caligiuri using cytokine therapies to modulate NK cells.

CytoImmune Therapeutics is translating a CAR NK cell platform targeting AML, B cell malignancies and multiple myeloma to the clinic, as well as pancreatic, stomach, bladder, prostate and lung cancer. New drug registrations under investigation are underway or planned for the use of CAR NK cells in these liquid and solid tumors in 2021.

About CytoImmune Therapeutics Inc.

CytoImmune Therapeutics was founded on the expansion of the natural killer cell and on the transduction technology developed by Yu and Caligiuri. The company is focused on expanding its manufacturing technologies to allow for numerous clinical studies on a variety of cancers.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other potentially fatal diseases. Founded in 1913, City of Hope is a leader in Bone marrow transplant and immunotherapy, as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols promote service worldwide. Human synthetic insulin, monoclonal antibodies and numerous innovative cancer drugs are based on technology developed at the institution. Translational Genomics Research Institute (TGen) became part of the City of Hope in 2016. AccessHopeTM, a wholly owned subsidiary, was launched in 2019, dedicated to serving employers and their healthcare partners by providing access to City of Hope’s exceptional cancer experience. Comprehensive cancer center designated by the National Cancer Institute and a founding member of the National Comprehensive Cancer Network, the City of Hope is ranked among the country’s “best hospitals” in cancer by the U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations across Southern California and Arizona. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

See the source version at businesswire.com: https://www.businesswire.com/news/home/20210408005072/en/

Contacts

CytoImmune
William Rosellini
will@cytoimmune.com

City of hope
Zen Vuong
626-409-9367
zvuong@coh.org



Paula Fonseca